Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...

This article presents a comprehensive overview of the molecular mechanisms underlying the anti-cancer properties of ICA, and further highlights recent progress in use of ICA in cancer research, ...

PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.

This article presents a comprehensive overview of the molecular mechanisms underlying the anti-cancer properties of ICA, and further highlights recent progress in use of ICA in cancer research, ...

CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...